Premium
Niacin for Parkinson's disease
Author(s) -
Seamon Marissa,
Purohit Sharad,
Giri Banabihari,
Baban Babak,
Morgan John,
Chong Raymond,
Wakade Chandramohan
Publication year - 2020
Publication title -
clinical and experimental neuroimmunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.297
H-Index - 15
ISSN - 1759-1961
DOI - 10.1111/cen3.12553
Subject(s) - neuroinflammation , medicine , coenzyme q10 , niacin , parkinson's disease , cognitive decline , disease , clinical trial , population , dementia , environmental health
Parkinson's disease (PD) is a neurodegenerative disease associated with progressive loss of motor function and cognitive decline occurring in 1% of the USA population. There is no cure for PD, and current treatment regimens are directed towards treating symptoms and not treating the underlying cause of the disease. Chronic neuroinflammation is associated with loss of neuronal cells, leading to motor and cognitive decline. Current clinical trials on drugs and nutraceuticals, such as coenzyme Q10 and niacin, are being carried out to delay progression and reduce damage by inflammatory molecules, such as reactive oxygen species and cytokines, in PD patients. In this review, we present available clinical trials and the role of niacin in reducing neuroinflammation in PD.